NOV 09, 2020 10:00 AM PST


  • Professor and Clinician Scientist, Western University

      Dr. Fraser is a Professor and Clinician Scientist in Critical Care/Trauma Medicine at Western University and Lawson Health Research Institute. With the emergence of SARS-CoV-2 (COVID-19), Dr. Fraser and his team quickly expanded their research capabilities to better understand this new threat to human health. With a growing number of SARS-CoV-2 peer-reviewed publications, 4 provisional patents and numerous media features, Dr. Fraser has become the authority on COVID19 diagnostics, prognostics and pathophysiology. In particular, Dr. Fraser and his team have profiled critically ill SARS-CoV-2 (COVID19) subjects for changes in their transcriptiome, metabolome and proteome, with specific emphasis on understanding the immune response. Dr. Fraser received his MD/PhD in Physiology and Biophysics at the University of Calgary (Alberta, Canada). He was the recipient of numerous Pre- and Post-Doctoral research awards from the Medical Research Council as well as other agencies. He subsequently completed his Medical Residency at Queen’s University, and then he received clinical fellowship training at the University of Ottawa in Critical Care Medicine. Dr. Fraser has received prestigious international training research awards, as well as a Canadian Institutes of Health Research (CIHR) Strategic Training Fellowship. He is a Fellow of the Royal College of Physicians and Surgeons of Canada. He has received multiple Innovation Awards and he was recently recognized as a ‘Scientist of the Year’. He is a Founder and Chief Medical Officer of NeuroLytixs, Inc., a diagnostics-based biotech company.


    Date:  November 9th, 2020

    Time: 10:00am PDT


    SARS-CoV-2 continues to spread rapidly with critically ill patients admitted to the intensive care unit (ICU), where the mortality rate is reported to be 31-40%. This webinar will present multiple SARS-CoV-2 investigations to elucidate pathophysiology of subjects suspected of being infected with SARS-CoV-2 and admitted to the ICU using standardized hospital screening methodologies. Specifically, blood samples were collected until either testing was confirmed SARS-CoV-2 negative on ICU day 3, or until ICU discharge/death if the subject tested SARS-CoV-2 positive. Blood samples were profiled using multiple state-of-the-art technologies. Our data suggest that SARS-CoV-2 infection causes an excessive release of inflammatory mediators, including TNF and serine proteases, together with microvascular thrombi formation secondary to endothelial injury/activation and glycocalyx degradation. Targeted metabolomics identified SARS-CoV-2 metabolite changes that may be useful diagnostically, while targeted proteomics identified novel SARS-CoV-2 outcome prognostic biomarkers. Finally, critically ill SARS-CoV-2 subjects demonstrate robust serological responses dominated by significant elevations in selective SARS-CoV-2 IgG. Taken together, our data demonstrate that SARS-CoV-2 initiates a unique immune response with our recent studies elucidating key pathophysiological mechanisms.


    Learning Objectives:

    • Provide new insight on the SARS-CoV-2 Immune Response
    • Introduce Novel SARS-CoV-2 Diagnostic and Prognostic Biomarkers
    • Value of ProcartaPlex Human Coronavirus Ig total 11-plex Panel


    Webinars will be available for unlimited on-demand viewing after live event.


    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

    Show Resources
    Show Resources
    • See more
    Connect with us